Drug Profile

Aceclidine - Lenz Therapeutics

Alternative Names: LNZ-100; VIZZ

Latest Information Update: 08 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator LENZ Therapeutics
Developer Corxel Pharmaceuticals; LENZ Therapeutics; Lotus Pharmaceuticals
Class Antiglaucomas; Azabicyclo compounds; Eye disorder therapies; Small molecules
Mechanism of Action Cholinergic receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Presbyopia

Highest Development Phases

Marketed Presbyopia

Most Recent Events

02 Dec 2025 Preregistration for Presbyopia in South Korea (Ophthalmic)
30 Sep 2025 Aceclidine - Lenz Therapeutics is available for licensing in World as of 30 Sep 2025. www.lenztx.com
30 Sep 2025 Launched for Presbyopia in USA (Ophthalmic)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com